Clinical trials: Hydroxychloroquine
Coronavirus, Corona Virus Infection
PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine
The proposed hypothesis is that high doses of hydroxychloroquine (HCQ) for at least 2 weeks can be effective antiviral medication both as a treatment in ambulatory patients and prophylaxis/treatment in health care workers because…
- Trial name
- NCT04353037
- Testing
- Group 1 HCQ
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- UnitedHealth Group
Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
The purpose of this study is to examine the combination of one standard treatment for lung cancer plus an additional drug, hydroxychloroquine.
- Conditions
- Non-small Cell Lung Cancer, Advanced Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01649947
- Testing
- Paclitaxel, Carboplatin, Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Rutgers, The State University of New Jersey
Colorectal Cancer
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
This will be a randomized phase II clinical trial of patients with histologic documentation of metastatic colorectal cancer, who have received local and currently approved standard therapies, excluding RGF.
- Trial name
- NCT02316340
- Testing
- Vorinostat, Hydroxychloroquine, Regorafenib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Prostate Cancer Recurrent
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
Treatment of recurrent oligometastatic prostate cancer may be enhanced by the addition of Hydroxychloroquine to the current treatment regimens.
- Trial name
- NCT04011410
- Testing
- Hydroxychloroquine Sulfate 200Mg Tab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Patrick Hensley
Virus Diseases, Infection Viral
Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19
This study explores whether patients acutely hospitalized may have shorter hospitalization and fewer admittances at Intensive Care Units by treatment with azithromycin and hydroxychloroquine.
- Conditions
- Virus Diseases, Infection Viral, Corona Virus Infection
- Trial name
- ProPAC-COVID (NCT04322396)
- Testing
- Azithromycin, Hydroxychloroquine
- Where
- 8 sites in Denmark
- Volunteers
- 117 people
- Sponsor
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
Tumor, Solid, Gastrointestinal Cancer
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
This is an open-label, prospective phase two basket trial assessing the efficacy of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies.
- Trial name
- NCT05221320
- Testing
- Ulixertinib, Hydroxychloroquine
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- BioMed Valley Discoveries, Inc
Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
- Conditions
- Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT04669197
- Testing
- Paclitaxel protein bound, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- HonorHealth Research Institute
Kidney Failure, Chronic, Cardiovascular Disease
Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study
Presence of multiple traditional and nontraditional risk factors of atherosclerosis and cardiovascular disease (CVD) including inflammation in patients with chronic kidney disease (CKD) contribute to high CVD morbidity and…
- Conditions
- Kidney Failure, Chronic, Cardiovascular Disease, Arteriosclerosis
- Trial name
- NCT01537315
- Testing
- Hydroxychloroquine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Arkansas
Pancreatic Cancer
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Hydroxychloroquine is approved for the treatment of non-cancerous illnesses such as rheumatoid arthritis and systemic lupus erythematous.
- Trial name
- NCT01273805
- Testing
- Hydroxychloroquine
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Chronic Pancreatitis, Insulin Dependent Diabetes
Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT
This will be a pilot, 12-month phase II, open label, randomized, two-arm, single-blinded, placebo-controlled, parallel clinical trial of individuals undergoing TPAIT (Total Pancreatectomy and Autologous Islet Transplantation) for…
- Trial name
- NCT03283566
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The Cleveland Clinic
COVID-19, Corona Virus Infection
Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)
The purpose of this study is to test the hypothesis that post-exposure prophylaxis with hydroxychloroquine will reduce the symptomatic secondary attack rate among household contacts of known or suspected COVID-19 patients.
- Trial name
- NCT04318444
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Columbia University
Type 2 Diabetes Mellitus
Metabolic Effects of Hydroxychloroquine
The basic plan of the study is to randomize otherwise healthy subjects with type 2 diabetes to hydroxychloroquine, 200 mg twice daily or placebo.
- Trial name
- MetaHcQ (NCT02026232)
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
Antiphospholipid Syndrome
Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients
In this multi-center international study, our aim is to determine the effectiveness of HCQ for primary thrombosis prophylaxis in persistently aPL-positive but thrombosis-free patients without systemic autoimmune diseases.
- Trial name
- NCT01784523
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Hospital for Special Surgery, New York
COVID-19, Corona Virus Infection
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons…
- Conditions
- COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
- Trial name
- NCT04328961
- Testing
- Hydroxychloroquine Sulfate, Ascorbic Acid
- Where
- 8 sites in United States
- Volunteers
- 943 people, healthy volunteers welcome
- Sponsor
- University of Washington
Individuals Undergoing Cardiac and General Surgery
Hydroxychloroquine and Cognitive Function After Surgery
The purpose of this study is to determine whether hydroxychloroquine decreases the relative leakage of the brain barrier after surgery.
- Trial name
- NCT03025087
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Chronic Kidney Disease, Cardiovascular Disease
Management of Cardiovascular Disease in Kidney Disease (MaCK) Study
Cardiovascular disease (CVD) is the largest concerns for patients with Chronic kidney disease (CKD). At present time the investigators do not have proven effective strategies to reduce high CVD related deaths in CKD.
- Conditions
- Chronic Kidney Disease, Cardiovascular Disease, Inflammation, Atherosclerosis
- Trial name
- MaCK (NCT03636152)
- Testing
- MRI carotid, APWV, Hydroxychloroquine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- VA Office of Research and Development
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
This phase I/II trial studies the side effects and best dose of hydroxychloroquine when given together with palbociclib and letrozole before surgery in treating patients with estrogen receptor positive, HER2 negative breast…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT03774472
- Testing
- Hydroxychloroquine, Letrozole, Palbociclib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
SARS-CoV-2, COVID-19
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19
This is a three-arm randomized trial comparing the efficacy of single agent hydroxychloroquine to the combination of hydroxychloroquine and azithromycin, and to a delayed hydroxychloroquine regimen, which will serve as a…
- Trial name
- NCT04336332
- Testing
- Hydroxychloroquine Sulfate + Azithromycin, Hydroxychloroquine Sulfate
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Rutgers, The State University of New Jersey
COVID-19, SARS-CoV 2
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19
The purpose of this study was to evaluate the efficacy of hydroxychloroquine (HCQ) and azithromycin (Azithro) to prevent hospitalization or death in symptomatic adult outpatients with COVID-19 caused by SARS-CoV-2 infection.
- Trial name
- NCT04358068
- Testing
- Hydroxychloroquine (HCQ), Azithromycin (Azithro)
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)